Abstract
Response to sulfasalazine was studied for 1 year in 45 patients with rheumatoid arthritis. Twenty-two patients achieved a satisfactory clinical response. Adverse reactions developed in 15. Hemoglobin rose, and platelet count, erythrocyte sedimentation rate, rheumatoid factor titer, immunoglobulins, and C3 component of complement fell in relation to degree of response. At 1 year, 18 patients elected to continue the treatment. No relationship between clinical response, adverse reactions, or laboratory changes and drug disposition was observed.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylation
-
Adult
-
Aged
-
Antibodies / immunology
-
Arthritis, Rheumatoid / blood
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / epidemiology
-
Arthritis, Rheumatoid / pathology
-
Clinical Trials as Topic
-
Complement System Proteins / analysis
-
DNA / immunology
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Immunoglobulins / analysis
-
Male
-
Middle Aged
-
Prognosis
-
Prospective Studies
-
Sulfasalazine / adverse effects
-
Sulfasalazine / blood
-
Sulfasalazine / therapeutic use*
Substances
-
Antibodies
-
Immunoglobulins
-
Sulfasalazine
-
Complement System Proteins
-
DNA